nodes	percent_of_prediction	percent_of_DWPC	metapath
Mexiletine—CYP3A4—bone cancer	0.772	1	CbGaD
Mexiletine—Pulmonary toxicity—Cisplatin—bone cancer	0.0072	0.0522	CcSEcCtD
Mexiletine—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00609	0.0724	CbGpPWpGaD
Mexiletine—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00434	0.0515	CbGpPWpGaD
Mexiletine—Speech impairment NOS—Methotrexate—bone cancer	0.00411	0.0298	CcSEcCtD
Mexiletine—Cardiogenic shock—Epirubicin—bone cancer	0.00401	0.029	CcSEcCtD
Mexiletine—Pulmonary toxicity—Methotrexate—bone cancer	0.00395	0.0286	CcSEcCtD
Mexiletine—Cardiogenic shock—Doxorubicin—bone cancer	0.00371	0.0268	CcSEcCtD
Mexiletine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00366	0.0435	CbGpPWpGaD
Mexiletine—AHR—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00271	0.0322	CbGpPWpGaD
Mexiletine—CYP2B6—Cisplatin—bone cancer	0.00269	0.455	CbGbCtD
Mexiletine—Oesophageal ulcer—Epirubicin—bone cancer	0.0023	0.0167	CcSEcCtD
Mexiletine—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.00215	0.0256	CbGpPWpGaD
Mexiletine—Oesophageal ulcer—Doxorubicin—bone cancer	0.00213	0.0154	CcSEcCtD
Mexiletine—CYP2B6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00204	0.0243	CbGpPWpGaD
Mexiletine—Pulmonary fibrosis—Methotrexate—bone cancer	0.00204	0.0148	CcSEcCtD
Mexiletine—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.002	0.0238	CbGpPWpGaD
Mexiletine—Lung infiltration—Methotrexate—bone cancer	0.00191	0.0139	CcSEcCtD
Mexiletine—CYP2B6—Doxorubicin—bone cancer	0.0018	0.305	CbGbCtD
Mexiletine—CYP2B6—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00172	0.0204	CbGpPWpGaD
Mexiletine—Pain—Carboplatin—bone cancer	0.0017	0.0123	CcSEcCtD
Mexiletine—Hiccups—Cisplatin—bone cancer	0.00163	0.0118	CcSEcCtD
Mexiletine—Body temperature increased—Carboplatin—bone cancer	0.00157	0.0114	CcSEcCtD
Mexiletine—AHR—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00146	0.0173	CbGpPWpGaD
Mexiletine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00143	0.0169	CbGpPWpGaD
Mexiletine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00142	0.0169	CbGpPWpGaD
Mexiletine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00134	0.016	CbGpPWpGaD
Mexiletine—Cardiac failure congestive—Cisplatin—bone cancer	0.00131	0.00948	CcSEcCtD
Mexiletine—Amnesia—Cisplatin—bone cancer	0.00126	0.00915	CcSEcCtD
Mexiletine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0012	0.0143	CbGpPWpGaD
Mexiletine—AHR—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.0012	0.0142	CbGpPWpGaD
Mexiletine—Nystagmus—Epirubicin—bone cancer	0.00118	0.00851	CcSEcCtD
Mexiletine—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00115	0.0137	CbGpPWpGaD
Mexiletine—Ventricular arrhythmia—Epirubicin—bone cancer	0.00113	0.00821	CcSEcCtD
Mexiletine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0011	0.0131	CbGpPWpGaD
Mexiletine—Nystagmus—Doxorubicin—bone cancer	0.00109	0.00788	CcSEcCtD
Mexiletine—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00108	0.0128	CbGpPWpGaD
Mexiletine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00108	0.0128	CbGpPWpGaD
Mexiletine—AHR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00107	0.0127	CbGpPWpGaD
Mexiletine—Cramp muscle—Cisplatin—bone cancer	0.00107	0.00774	CcSEcCtD
Mexiletine—Ventricular arrhythmia—Doxorubicin—bone cancer	0.00105	0.0076	CcSEcCtD
Mexiletine—Speech disorder—Methotrexate—bone cancer	0.00104	0.00755	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00103	0.0123	CbGpPWpGaD
Mexiletine—Pancreatitis—Cisplatin—bone cancer	0.00101	0.00728	CcSEcCtD
Mexiletine—Blood disorder—Epirubicin—bone cancer	0.001	0.00728	CcSEcCtD
Mexiletine—Sweating increased—Cisplatin—bone cancer	0.000999	0.00724	CcSEcCtD
Mexiletine—CYP2B6—Xenobiotics—CYP3A4—bone cancer	0.000985	0.0117	CbGpPWpGaD
Mexiletine—Abdominal discomfort—Cisplatin—bone cancer	0.000983	0.00712	CcSEcCtD
Mexiletine—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000965	0.0115	CbGpPWpGaD
Mexiletine—Blood disorder—Doxorubicin—bone cancer	0.00093	0.00674	CcSEcCtD
Mexiletine—Ventricular extrasystoles—Epirubicin—bone cancer	0.000929	0.00673	CcSEcCtD
Mexiletine—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000928	0.011	CbGpPWpGaD
Mexiletine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000928	0.011	CbGpPWpGaD
Mexiletine—AHR—Circadian rythm related genes—GNA11—bone cancer	0.000917	0.0109	CbGpPWpGaD
Mexiletine—AHR—Circadian rythm related genes—EZH2—bone cancer	0.000913	0.0109	CbGpPWpGaD
Mexiletine—AHR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000894	0.0106	CbGpPWpGaD
Mexiletine—CYP2B6—Metapathway biotransformation—CYP4V2—bone cancer	0.000879	0.0104	CbGpPWpGaD
Mexiletine—AHR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000874	0.0104	CbGpPWpGaD
Mexiletine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000873	0.0104	CbGpPWpGaD
Mexiletine—CYP2D6—Doxorubicin—bone cancer	0.000872	0.147	CbGbCtD
Mexiletine—Atrioventricular block—Epirubicin—bone cancer	0.000865	0.00627	CcSEcCtD
Mexiletine—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000861	0.0102	CbGpPWpGaD
Mexiletine—Ventricular extrasystoles—Doxorubicin—bone cancer	0.00086	0.00623	CcSEcCtD
Mexiletine—Coordination abnormal—Epirubicin—bone cancer	0.000855	0.00619	CcSEcCtD
Mexiletine—AHR—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00085	0.0101	CbGpPWpGaD
Mexiletine—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00085	0.0101	CbGpPWpGaD
Mexiletine—Hiccups—Epirubicin—bone cancer	0.000839	0.00608	CcSEcCtD
Mexiletine—Bradycardia—Cisplatin—bone cancer	0.000836	0.00605	CcSEcCtD
Mexiletine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000819	0.00973	CbGpPWpGaD
Mexiletine—Atrioventricular block—Doxorubicin—bone cancer	0.000801	0.0058	CcSEcCtD
Mexiletine—Visual impairment—Cisplatin—bone cancer	0.000791	0.00573	CcSEcCtD
Mexiletine—Coordination abnormal—Doxorubicin—bone cancer	0.000791	0.00573	CcSEcCtD
Mexiletine—Hiccups—Doxorubicin—bone cancer	0.000777	0.00563	CcSEcCtD
Mexiletine—Tinnitus—Cisplatin—bone cancer	0.000765	0.00554	CcSEcCtD
Mexiletine—Arrhythmia—Cisplatin—bone cancer	0.000733	0.00531	CcSEcCtD
Mexiletine—Alopecia—Cisplatin—bone cancer	0.000725	0.00525	CcSEcCtD
Mexiletine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000694	0.00824	CbGpPWpGaD
Mexiletine—Dermatitis exfoliative—Methotrexate—bone cancer	0.00069	0.005	CcSEcCtD
Mexiletine—Visual disturbance—Methotrexate—bone cancer	0.000687	0.00498	CcSEcCtD
Mexiletine—Muscle spasms—Cisplatin—bone cancer	0.000687	0.00498	CcSEcCtD
Mexiletine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000685	0.00814	CbGpPWpGaD
Mexiletine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000677	0.00804	CbGpPWpGaD
Mexiletine—Vision blurred—Cisplatin—bone cancer	0.000673	0.00488	CcSEcCtD
Mexiletine—Cardiac failure congestive—Epirubicin—bone cancer	0.000672	0.00487	CcSEcCtD
Mexiletine—Tremor—Cisplatin—bone cancer	0.000669	0.00485	CcSEcCtD
Mexiletine—Ill-defined disorder—Cisplatin—bone cancer	0.000663	0.0048	CcSEcCtD
Mexiletine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000659	0.00783	CbGpPWpGaD
Mexiletine—Hot flush—Epirubicin—bone cancer	0.000651	0.00472	CcSEcCtD
Mexiletine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00065	0.00772	CbGpPWpGaD
Mexiletine—AHR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000648	0.0077	CbGpPWpGaD
Mexiletine—Menopausal symptoms—Epirubicin—bone cancer	0.000646	0.00468	CcSEcCtD
Mexiletine—Dermatitis exfoliative—Epirubicin—bone cancer	0.000646	0.00468	CcSEcCtD
Mexiletine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000645	0.00766	CbGpPWpGaD
Mexiletine—Malaise—Cisplatin—bone cancer	0.000644	0.00467	CcSEcCtD
Mexiletine—Leukopenia—Cisplatin—bone cancer	0.00064	0.00463	CcSEcCtD
Mexiletine—AHR—Adipogenesis—RB1—bone cancer	0.000635	0.00755	CbGpPWpGaD
Mexiletine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000631	0.0075	CbGpPWpGaD
Mexiletine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000631	0.0075	CbGpPWpGaD
Mexiletine—Cardiac failure congestive—Doxorubicin—bone cancer	0.000622	0.0045	CcSEcCtD
Mexiletine—Convulsion—Cisplatin—bone cancer	0.000619	0.00448	CcSEcCtD
Mexiletine—Ataxia—Methotrexate—bone cancer	0.000612	0.00443	CcSEcCtD
Mexiletine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000611	0.00726	CbGpPWpGaD
Mexiletine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000605	0.00719	CbGpPWpGaD
Mexiletine—Hot flush—Doxorubicin—bone cancer	0.000603	0.00437	CcSEcCtD
Mexiletine—Liver function test abnormal—Methotrexate—bone cancer	0.000601	0.00435	CcSEcCtD
Mexiletine—Discomfort—Cisplatin—bone cancer	0.000601	0.00435	CcSEcCtD
Mexiletine—Menopausal symptoms—Doxorubicin—bone cancer	0.000597	0.00433	CcSEcCtD
Mexiletine—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000597	0.00433	CcSEcCtD
Mexiletine—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000589	0.007	CbGpPWpGaD
Mexiletine—Oedema—Cisplatin—bone cancer	0.000583	0.00422	CcSEcCtD
Mexiletine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00058	0.0069	CbGpPWpGaD
Mexiletine—AHR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000573	0.00682	CbGpPWpGaD
Mexiletine—Ataxia—Epirubicin—bone cancer	0.000573	0.00415	CcSEcCtD
Mexiletine—Thrombocytopenia—Cisplatin—bone cancer	0.000571	0.00414	CcSEcCtD
Mexiletine—Hyperhidrosis—Cisplatin—bone cancer	0.000564	0.00408	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000564	0.0067	CbGpPWpGaD
Mexiletine—Liver function test abnormal—Epirubicin—bone cancer	0.000563	0.00407	CcSEcCtD
Mexiletine—Dry skin—Epirubicin—bone cancer	0.000558	0.00405	CcSEcCtD
Mexiletine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000558	0.00663	CbGpPWpGaD
Mexiletine—CYP3A4—Doxorubicin—bone cancer	0.000554	0.0936	CbGbCtD
Mexiletine—Pancreatitis—Methotrexate—bone cancer	0.000552	0.004	CcSEcCtD
Mexiletine—Hypotension—Cisplatin—bone cancer	0.000545	0.00395	CcSEcCtD
Mexiletine—Abdominal discomfort—Methotrexate—bone cancer	0.000539	0.00391	CcSEcCtD
Mexiletine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000531	0.00385	CcSEcCtD
Mexiletine—Ataxia—Doxorubicin—bone cancer	0.00053	0.00384	CcSEcCtD
Mexiletine—Dysphagia—Epirubicin—bone cancer	0.000527	0.00381	CcSEcCtD
Mexiletine—Neutropenia—Methotrexate—bone cancer	0.000526	0.00381	CcSEcCtD
Mexiletine—Paraesthesia—Cisplatin—bone cancer	0.000524	0.00379	CcSEcCtD
Mexiletine—Liver function test abnormal—Doxorubicin—bone cancer	0.00052	0.00377	CcSEcCtD
Mexiletine—Dyspnoea—Cisplatin—bone cancer	0.00052	0.00377	CcSEcCtD
Mexiletine—Erectile dysfunction—Methotrexate—bone cancer	0.000518	0.00375	CcSEcCtD
Mexiletine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000517	0.00615	CbGpPWpGaD
Mexiletine—Dry skin—Doxorubicin—bone cancer	0.000517	0.00374	CcSEcCtD
Mexiletine—Pancreatitis—Epirubicin—bone cancer	0.000516	0.00374	CcSEcCtD
Mexiletine—AHR—Circadian rythm related genes—CDK4—bone cancer	0.000516	0.00613	CbGpPWpGaD
Mexiletine—Angina pectoris—Epirubicin—bone cancer	0.000513	0.00372	CcSEcCtD
Mexiletine—Drowsiness—Methotrexate—bone cancer	0.000502	0.00363	CcSEcCtD
Mexiletine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000501	0.00596	CbGpPWpGaD
Mexiletine—Depression—Methotrexate—bone cancer	0.0005	0.00362	CcSEcCtD
Mexiletine—Pain—Cisplatin—bone cancer	0.000499	0.00361	CcSEcCtD
Mexiletine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000497	0.0036	CcSEcCtD
Mexiletine—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000496	0.00589	CbGpPWpGaD
Mexiletine—Neutropenia—Epirubicin—bone cancer	0.000492	0.00357	CcSEcCtD
Mexiletine—Dysphagia—Doxorubicin—bone cancer	0.000487	0.00353	CcSEcCtD
Mexiletine—Feeling abnormal—Cisplatin—bone cancer	0.000481	0.00348	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00048	0.00571	CbGpPWpGaD
Mexiletine—Pancreatitis—Doxorubicin—bone cancer	0.000478	0.00346	CcSEcCtD
Mexiletine—Angina pectoris—Doxorubicin—bone cancer	0.000475	0.00344	CcSEcCtD
Mexiletine—Drowsiness—Epirubicin—bone cancer	0.00047	0.0034	CcSEcCtD
Mexiletine—Agranulocytosis—Methotrexate—bone cancer	0.000468	0.00339	CcSEcCtD
Mexiletine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000465	0.00337	CcSEcCtD
Mexiletine—Body temperature increased—Cisplatin—bone cancer	0.000461	0.00334	CcSEcCtD
Mexiletine—Neutropenia—Doxorubicin—bone cancer	0.000456	0.0033	CcSEcCtD
Mexiletine—Hepatitis—Methotrexate—bone cancer	0.00045	0.00326	CcSEcCtD
Mexiletine—Pharyngitis—Methotrexate—bone cancer	0.000447	0.00324	CcSEcCtD
Mexiletine—Agranulocytosis—Epirubicin—bone cancer	0.000438	0.00317	CcSEcCtD
Mexiletine—Drowsiness—Doxorubicin—bone cancer	0.000434	0.00315	CcSEcCtD
Mexiletine—Visual impairment—Methotrexate—bone cancer	0.000434	0.00314	CcSEcCtD
Mexiletine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000431	0.00312	CcSEcCtD
Mexiletine—Hypersensitivity—Cisplatin—bone cancer	0.00043	0.00311	CcSEcCtD
Mexiletine—Bradycardia—Epirubicin—bone cancer	0.000429	0.00311	CcSEcCtD
Mexiletine—Erythema multiforme—Methotrexate—bone cancer	0.000426	0.00308	CcSEcCtD
Mexiletine—Hepatitis—Epirubicin—bone cancer	0.000421	0.00305	CcSEcCtD
Mexiletine—Tinnitus—Methotrexate—bone cancer	0.00042	0.00304	CcSEcCtD
Mexiletine—Hypoaesthesia—Epirubicin—bone cancer	0.000419	0.00304	CcSEcCtD
Mexiletine—Asthenia—Cisplatin—bone cancer	0.000418	0.00303	CcSEcCtD
Mexiletine—Pharyngitis—Epirubicin—bone cancer	0.000418	0.00303	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000418	0.00496	CbGpPWpGaD
Mexiletine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000409	0.00486	CbGpPWpGaD
Mexiletine—Visual impairment—Epirubicin—bone cancer	0.000406	0.00294	CcSEcCtD
Mexiletine—Agranulocytosis—Doxorubicin—bone cancer	0.000405	0.00294	CcSEcCtD
Mexiletine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000404	0.0048	CbGpPWpGaD
Mexiletine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000401	0.00476	CbGpPWpGaD
Mexiletine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000399	0.00475	CbGpPWpGaD
Mexiletine—Diarrhoea—Cisplatin—bone cancer	0.000399	0.00289	CcSEcCtD
Mexiletine—Erythema multiforme—Epirubicin—bone cancer	0.000399	0.00289	CcSEcCtD
Mexiletine—Alopecia—Methotrexate—bone cancer	0.000398	0.00288	CcSEcCtD
Mexiletine—Bradycardia—Doxorubicin—bone cancer	0.000397	0.00288	CcSEcCtD
Mexiletine—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000396	0.0047	CbGpPWpGaD
Mexiletine—Tinnitus—Epirubicin—bone cancer	0.000393	0.00285	CcSEcCtD
Mexiletine—Hepatitis—Doxorubicin—bone cancer	0.00039	0.00283	CcSEcCtD
Mexiletine—Hypoaesthesia—Doxorubicin—bone cancer	0.000388	0.00281	CcSEcCtD
Mexiletine—Pharyngitis—Doxorubicin—bone cancer	0.000387	0.0028	CcSEcCtD
Mexiletine—Dysgeusia—Methotrexate—bone cancer	0.000384	0.00278	CcSEcCtD
Mexiletine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00038	0.00451	CbGpPWpGaD
Mexiletine—Arrhythmia—Epirubicin—bone cancer	0.000377	0.00273	CcSEcCtD
Mexiletine—Visual impairment—Doxorubicin—bone cancer	0.000376	0.00272	CcSEcCtD
Mexiletine—Alopecia—Epirubicin—bone cancer	0.000372	0.0027	CcSEcCtD
Mexiletine—Vomiting—Cisplatin—bone cancer	0.000371	0.00269	CcSEcCtD
Mexiletine—Vision blurred—Methotrexate—bone cancer	0.00037	0.00268	CcSEcCtD
Mexiletine—Erythema multiforme—Doxorubicin—bone cancer	0.000369	0.00267	CcSEcCtD
Mexiletine—Rash—Cisplatin—bone cancer	0.000368	0.00266	CcSEcCtD
Mexiletine—Dermatitis—Cisplatin—bone cancer	0.000367	0.00266	CcSEcCtD
Mexiletine—Ill-defined disorder—Methotrexate—bone cancer	0.000364	0.00264	CcSEcCtD
Mexiletine—Tinnitus—Doxorubicin—bone cancer	0.000364	0.00263	CcSEcCtD
Mexiletine—Tension—Epirubicin—bone cancer	0.00036	0.00261	CcSEcCtD
Mexiletine—Dysgeusia—Epirubicin—bone cancer	0.000359	0.0026	CcSEcCtD
Mexiletine—Nervousness—Epirubicin—bone cancer	0.000356	0.00258	CcSEcCtD
Mexiletine—Malaise—Methotrexate—bone cancer	0.000354	0.00256	CcSEcCtD
Mexiletine—Muscle spasms—Epirubicin—bone cancer	0.000353	0.00256	CcSEcCtD
Mexiletine—Leukopenia—Methotrexate—bone cancer	0.000351	0.00254	CcSEcCtD
Mexiletine—Arrhythmia—Doxorubicin—bone cancer	0.000348	0.00252	CcSEcCtD
Mexiletine—Nausea—Cisplatin—bone cancer	0.000346	0.00251	CcSEcCtD
Mexiletine—Vision blurred—Epirubicin—bone cancer	0.000346	0.0025	CcSEcCtD
Mexiletine—Alopecia—Doxorubicin—bone cancer	0.000345	0.0025	CcSEcCtD
Mexiletine—Ill-defined disorder—Epirubicin—bone cancer	0.00034	0.00247	CcSEcCtD
Mexiletine—Convulsion—Methotrexate—bone cancer	0.00034	0.00246	CcSEcCtD
Mexiletine—Chest pain—Methotrexate—bone cancer	0.000334	0.00242	CcSEcCtD
Mexiletine—Arthralgia—Methotrexate—bone cancer	0.000334	0.00242	CcSEcCtD
Mexiletine—Tension—Doxorubicin—bone cancer	0.000333	0.00241	CcSEcCtD
Mexiletine—Dysgeusia—Doxorubicin—bone cancer	0.000332	0.00241	CcSEcCtD
Mexiletine—AHR—Circadian rythm related genes—JUN—bone cancer	0.000332	0.00395	CbGpPWpGaD
Mexiletine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000332	0.00394	CbGpPWpGaD
Mexiletine—Malaise—Epirubicin—bone cancer	0.000331	0.0024	CcSEcCtD
Mexiletine—Discomfort—Methotrexate—bone cancer	0.00033	0.00239	CcSEcCtD
Mexiletine—Nervousness—Doxorubicin—bone cancer	0.00033	0.00239	CcSEcCtD
Mexiletine—Syncope—Epirubicin—bone cancer	0.000329	0.00238	CcSEcCtD
Mexiletine—Leukopenia—Epirubicin—bone cancer	0.000328	0.00238	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000328	0.0039	CbGpPWpGaD
Mexiletine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000327	0.00389	CbGpPWpGaD
Mexiletine—Muscle spasms—Doxorubicin—bone cancer	0.000326	0.00236	CcSEcCtD
Mexiletine—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000325	0.00386	CbGpPWpGaD
Mexiletine—Palpitations—Epirubicin—bone cancer	0.000324	0.00235	CcSEcCtD
Mexiletine—Confusional state—Methotrexate—bone cancer	0.000323	0.00234	CcSEcCtD
Mexiletine—Loss of consciousness—Epirubicin—bone cancer	0.000322	0.00234	CcSEcCtD
Mexiletine—Vision blurred—Doxorubicin—bone cancer	0.00032	0.00232	CcSEcCtD
Mexiletine—Convulsion—Epirubicin—bone cancer	0.000318	0.0023	CcSEcCtD
Mexiletine—Hypertension—Epirubicin—bone cancer	0.000317	0.00229	CcSEcCtD
Mexiletine—SCN9A—L1CAM interactions—EGFR—bone cancer	0.000316	0.00376	CbGpPWpGaD
Mexiletine—Ill-defined disorder—Doxorubicin—bone cancer	0.000315	0.00228	CcSEcCtD
Mexiletine—Thrombocytopenia—Methotrexate—bone cancer	0.000313	0.00227	CcSEcCtD
Mexiletine—Chest pain—Epirubicin—bone cancer	0.000312	0.00226	CcSEcCtD
Mexiletine—Arthralgia—Epirubicin—bone cancer	0.000312	0.00226	CcSEcCtD
Mexiletine—Hyperhidrosis—Methotrexate—bone cancer	0.000309	0.00224	CcSEcCtD
Mexiletine—Discomfort—Epirubicin—bone cancer	0.000309	0.00224	CcSEcCtD
Mexiletine—Malaise—Doxorubicin—bone cancer	0.000306	0.00222	CcSEcCtD
Mexiletine—Dry mouth—Epirubicin—bone cancer	0.000306	0.00221	CcSEcCtD
Mexiletine—Syncope—Doxorubicin—bone cancer	0.000304	0.00221	CcSEcCtD
Mexiletine—Leukopenia—Doxorubicin—bone cancer	0.000304	0.0022	CcSEcCtD
Mexiletine—Confusional state—Epirubicin—bone cancer	0.000302	0.00219	CcSEcCtD
Mexiletine—Palpitations—Doxorubicin—bone cancer	0.0003	0.00217	CcSEcCtD
Mexiletine—Oedema—Epirubicin—bone cancer	0.000299	0.00217	CcSEcCtD
Mexiletine—Hypotension—Methotrexate—bone cancer	0.000299	0.00217	CcSEcCtD
Mexiletine—Loss of consciousness—Doxorubicin—bone cancer	0.000298	0.00216	CcSEcCtD
Mexiletine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000298	0.00354	CbGpPWpGaD
Mexiletine—Shock—Epirubicin—bone cancer	0.000295	0.00213	CcSEcCtD
Mexiletine—Convulsion—Doxorubicin—bone cancer	0.000294	0.00213	CcSEcCtD
Mexiletine—Thrombocytopenia—Epirubicin—bone cancer	0.000293	0.00212	CcSEcCtD
Mexiletine—Hypertension—Doxorubicin—bone cancer	0.000293	0.00212	CcSEcCtD
Mexiletine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000292	0.00211	CcSEcCtD
Mexiletine—SCN2A—L1CAM interactions—EGFR—bone cancer	0.000291	0.00345	CbGpPWpGaD
Mexiletine—SCN4A—L1CAM interactions—EGFR—bone cancer	0.000291	0.00345	CbGpPWpGaD
Mexiletine—Hyperhidrosis—Epirubicin—bone cancer	0.000289	0.0021	CcSEcCtD
Mexiletine—Arthralgia—Doxorubicin—bone cancer	0.000289	0.00209	CcSEcCtD
Mexiletine—Chest pain—Doxorubicin—bone cancer	0.000289	0.00209	CcSEcCtD
Mexiletine—Paraesthesia—Methotrexate—bone cancer	0.000287	0.00208	CcSEcCtD
Mexiletine—Discomfort—Doxorubicin—bone cancer	0.000286	0.00207	CcSEcCtD
Mexiletine—Dyspnoea—Methotrexate—bone cancer	0.000285	0.00207	CcSEcCtD
Mexiletine—Somnolence—Methotrexate—bone cancer	0.000284	0.00206	CcSEcCtD
Mexiletine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000284	0.00338	CbGpPWpGaD
Mexiletine—Dry mouth—Doxorubicin—bone cancer	0.000283	0.00205	CcSEcCtD
Mexiletine—Dyspepsia—Methotrexate—bone cancer	0.000282	0.00204	CcSEcCtD
Mexiletine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000281	0.00334	CbGpPWpGaD
Mexiletine—SCN10A—L1CAM interactions—EGFR—bone cancer	0.00028	0.00333	CbGpPWpGaD
Mexiletine—Hypotension—Epirubicin—bone cancer	0.00028	0.00203	CcSEcCtD
Mexiletine—Confusional state—Doxorubicin—bone cancer	0.000279	0.00202	CcSEcCtD
Mexiletine—Oedema—Doxorubicin—bone cancer	0.000277	0.00201	CcSEcCtD
Mexiletine—Fatigue—Methotrexate—bone cancer	0.000276	0.002	CcSEcCtD
Mexiletine—AHR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000276	0.00328	CbGpPWpGaD
Mexiletine—Pain—Methotrexate—bone cancer	0.000274	0.00198	CcSEcCtD
Mexiletine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000273	0.00198	CcSEcCtD
Mexiletine—Shock—Doxorubicin—bone cancer	0.000273	0.00197	CcSEcCtD
Mexiletine—Thrombocytopenia—Doxorubicin—bone cancer	0.000271	0.00197	CcSEcCtD
Mexiletine—Paraesthesia—Epirubicin—bone cancer	0.000269	0.00195	CcSEcCtD
Mexiletine—Hyperhidrosis—Doxorubicin—bone cancer	0.000268	0.00194	CcSEcCtD
Mexiletine—Dyspnoea—Epirubicin—bone cancer	0.000267	0.00193	CcSEcCtD
Mexiletine—Somnolence—Epirubicin—bone cancer	0.000266	0.00193	CcSEcCtD
Mexiletine—Feeling abnormal—Methotrexate—bone cancer	0.000264	0.00191	CcSEcCtD
Mexiletine—Dyspepsia—Epirubicin—bone cancer	0.000264	0.00191	CcSEcCtD
Mexiletine—Gastrointestinal pain—Methotrexate—bone cancer	0.000262	0.0019	CcSEcCtD
Mexiletine—Hypotension—Doxorubicin—bone cancer	0.000259	0.00188	CcSEcCtD
Mexiletine—Fatigue—Epirubicin—bone cancer	0.000258	0.00187	CcSEcCtD
Mexiletine—Constipation—Epirubicin—bone cancer	0.000256	0.00186	CcSEcCtD
Mexiletine—Pain—Epirubicin—bone cancer	0.000256	0.00186	CcSEcCtD
Mexiletine—Abdominal pain—Methotrexate—bone cancer	0.000253	0.00183	CcSEcCtD
Mexiletine—Body temperature increased—Methotrexate—bone cancer	0.000253	0.00183	CcSEcCtD
Mexiletine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000252	0.00183	CcSEcCtD
Mexiletine—Paraesthesia—Doxorubicin—bone cancer	0.000249	0.0018	CcSEcCtD
Mexiletine—Dyspnoea—Doxorubicin—bone cancer	0.000247	0.00179	CcSEcCtD
Mexiletine—Feeling abnormal—Epirubicin—bone cancer	0.000247	0.00179	CcSEcCtD
Mexiletine—Somnolence—Doxorubicin—bone cancer	0.000246	0.00178	CcSEcCtD
Mexiletine—Gastrointestinal pain—Epirubicin—bone cancer	0.000245	0.00177	CcSEcCtD
Mexiletine—Dyspepsia—Doxorubicin—bone cancer	0.000244	0.00177	CcSEcCtD
Mexiletine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000241	0.00286	CbGpPWpGaD
Mexiletine—Fatigue—Doxorubicin—bone cancer	0.000239	0.00173	CcSEcCtD
Mexiletine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000238	0.00283	CbGpPWpGaD
Mexiletine—Constipation—Doxorubicin—bone cancer	0.000237	0.00172	CcSEcCtD
Mexiletine—Pain—Doxorubicin—bone cancer	0.000237	0.00172	CcSEcCtD
Mexiletine—Abdominal pain—Epirubicin—bone cancer	0.000237	0.00171	CcSEcCtD
Mexiletine—Body temperature increased—Epirubicin—bone cancer	0.000237	0.00171	CcSEcCtD
Mexiletine—SCN9A—Axon guidance—MET—bone cancer	0.000236	0.0028	CbGpPWpGaD
Mexiletine—Hypersensitivity—Methotrexate—bone cancer	0.000236	0.00171	CcSEcCtD
Mexiletine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000231	0.00274	CbGpPWpGaD
Mexiletine—Asthenia—Methotrexate—bone cancer	0.00023	0.00166	CcSEcCtD
Mexiletine—Feeling abnormal—Doxorubicin—bone cancer	0.000228	0.00165	CcSEcCtD
Mexiletine—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000228	0.00271	CbGpPWpGaD
Mexiletine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000227	0.00164	CcSEcCtD
Mexiletine—Hypersensitivity—Epirubicin—bone cancer	0.000221	0.0016	CcSEcCtD
Mexiletine—AHR—Circadian rythm related genes—TP53—bone cancer	0.000219	0.00261	CbGpPWpGaD
Mexiletine—Abdominal pain—Doxorubicin—bone cancer	0.000219	0.00159	CcSEcCtD
Mexiletine—Body temperature increased—Doxorubicin—bone cancer	0.000219	0.00159	CcSEcCtD
Mexiletine—Diarrhoea—Methotrexate—bone cancer	0.000219	0.00159	CcSEcCtD
Mexiletine—SCN2A—Axon guidance—MET—bone cancer	0.000217	0.00258	CbGpPWpGaD
Mexiletine—SCN4A—Axon guidance—MET—bone cancer	0.000217	0.00258	CbGpPWpGaD
Mexiletine—Asthenia—Epirubicin—bone cancer	0.000215	0.00156	CcSEcCtD
Mexiletine—Dizziness—Methotrexate—bone cancer	0.000212	0.00153	CcSEcCtD
Mexiletine—SCN10A—Axon guidance—MET—bone cancer	0.000209	0.00248	CbGpPWpGaD
Mexiletine—Diarrhoea—Epirubicin—bone cancer	0.000205	0.00148	CcSEcCtD
Mexiletine—Hypersensitivity—Doxorubicin—bone cancer	0.000204	0.00148	CcSEcCtD
Mexiletine—Vomiting—Methotrexate—bone cancer	0.000203	0.00147	CcSEcCtD
Mexiletine—Rash—Methotrexate—bone cancer	0.000202	0.00146	CcSEcCtD
Mexiletine—Dermatitis—Methotrexate—bone cancer	0.000202	0.00146	CcSEcCtD
Mexiletine—Headache—Methotrexate—bone cancer	0.0002	0.00145	CcSEcCtD
Mexiletine—Asthenia—Doxorubicin—bone cancer	0.000199	0.00144	CcSEcCtD
Mexiletine—Dizziness—Epirubicin—bone cancer	0.000198	0.00143	CcSEcCtD
Mexiletine—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000197	0.00234	CbGpPWpGaD
Mexiletine—SCN9A—Axon guidance—MMP2—bone cancer	0.000197	0.00234	CbGpPWpGaD
Mexiletine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000195	0.00232	CbGpPWpGaD
Mexiletine—Vomiting—Epirubicin—bone cancer	0.00019	0.00138	CcSEcCtD
Mexiletine—Nausea—Methotrexate—bone cancer	0.00019	0.00138	CcSEcCtD
Mexiletine—Diarrhoea—Doxorubicin—bone cancer	0.00019	0.00137	CcSEcCtD
Mexiletine—Rash—Epirubicin—bone cancer	0.000189	0.00137	CcSEcCtD
Mexiletine—Dermatitis—Epirubicin—bone cancer	0.000189	0.00137	CcSEcCtD
Mexiletine—Headache—Epirubicin—bone cancer	0.000188	0.00136	CcSEcCtD
Mexiletine—Dizziness—Doxorubicin—bone cancer	0.000183	0.00133	CcSEcCtD
Mexiletine—SCN2A—Axon guidance—MMP2—bone cancer	0.000181	0.00215	CbGpPWpGaD
Mexiletine—SCN4A—Axon guidance—MMP2—bone cancer	0.000181	0.00215	CbGpPWpGaD
Mexiletine—Nausea—Epirubicin—bone cancer	0.000178	0.00129	CcSEcCtD
Mexiletine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000176	0.00209	CbGpPWpGaD
Mexiletine—Vomiting—Doxorubicin—bone cancer	0.000176	0.00128	CcSEcCtD
Mexiletine—Rash—Doxorubicin—bone cancer	0.000175	0.00127	CcSEcCtD
Mexiletine—Dermatitis—Doxorubicin—bone cancer	0.000175	0.00126	CcSEcCtD
Mexiletine—SCN10A—Axon guidance—MMP2—bone cancer	0.000174	0.00207	CbGpPWpGaD
Mexiletine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000174	0.00207	CbGpPWpGaD
Mexiletine—Headache—Doxorubicin—bone cancer	0.000174	0.00126	CcSEcCtD
Mexiletine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000173	0.00205	CbGpPWpGaD
Mexiletine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.00017	0.00202	CbGpPWpGaD
Mexiletine—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.00017	0.00202	CbGpPWpGaD
Mexiletine—SCN9A—Developmental Biology—MET—bone cancer	0.000168	0.002	CbGpPWpGaD
Mexiletine—SCN9A—Developmental Biology—CDK4—bone cancer	0.000168	0.002	CbGpPWpGaD
Mexiletine—Nausea—Doxorubicin—bone cancer	0.000165	0.00119	CcSEcCtD
Mexiletine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000161	0.00191	CbGpPWpGaD
Mexiletine—SCN2A—Developmental Biology—CDK4—bone cancer	0.000155	0.00184	CbGpPWpGaD
Mexiletine—SCN4A—Developmental Biology—CDK4—bone cancer	0.000155	0.00184	CbGpPWpGaD
Mexiletine—SCN2A—Developmental Biology—MET—bone cancer	0.000155	0.00184	CbGpPWpGaD
Mexiletine—SCN4A—Developmental Biology—MET—bone cancer	0.000155	0.00184	CbGpPWpGaD
Mexiletine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000152	0.0018	CbGpPWpGaD
Mexiletine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000151	0.00179	CbGpPWpGaD
Mexiletine—SCN10A—Developmental Biology—CDK4—bone cancer	0.000149	0.00177	CbGpPWpGaD
Mexiletine—SCN10A—Developmental Biology—MET—bone cancer	0.000149	0.00177	CbGpPWpGaD
Mexiletine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000149	0.00177	CbGpPWpGaD
Mexiletine—SCN9A—Axon guidance—MMP9—bone cancer	0.000148	0.00176	CbGpPWpGaD
Mexiletine—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000148	0.00175	CbGpPWpGaD
Mexiletine—SCN5A—Axon guidance—MET—bone cancer	0.000147	0.00175	CbGpPWpGaD
Mexiletine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000146	0.00173	CbGpPWpGaD
Mexiletine—SCN9A—Developmental Biology—MMP2—bone cancer	0.00014	0.00167	CbGpPWpGaD
Mexiletine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000137	0.00163	CbGpPWpGaD
Mexiletine—SCN4A—Axon guidance—MMP9—bone cancer	0.000136	0.00161	CbGpPWpGaD
Mexiletine—SCN2A—Axon guidance—MMP9—bone cancer	0.000136	0.00161	CbGpPWpGaD
Mexiletine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000132	0.00157	CbGpPWpGaD
Mexiletine—SCN10A—Axon guidance—MMP9—bone cancer	0.000131	0.00156	CbGpPWpGaD
Mexiletine—SCN2A—Developmental Biology—MMP2—bone cancer	0.000129	0.00153	CbGpPWpGaD
Mexiletine—SCN4A—Developmental Biology—MMP2—bone cancer	0.000129	0.00153	CbGpPWpGaD
Mexiletine—SCN10A—Developmental Biology—MMP2—bone cancer	0.000124	0.00148	CbGpPWpGaD
Mexiletine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000124	0.00147	CbGpPWpGaD
Mexiletine—SCN5A—Axon guidance—MMP2—bone cancer	0.000123	0.00146	CbGpPWpGaD
Mexiletine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000122	0.00146	CbGpPWpGaD
Mexiletine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000121	0.00144	CbGpPWpGaD
Mexiletine—SCN9A—Axon guidance—EGFR—bone cancer	0.000119	0.00142	CbGpPWpGaD
Mexiletine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000119	0.00141	CbGpPWpGaD
Mexiletine—SCN2A—Axon guidance—EGFR—bone cancer	0.00011	0.0013	CbGpPWpGaD
Mexiletine—SCN4A—Axon guidance—EGFR—bone cancer	0.00011	0.0013	CbGpPWpGaD
Mexiletine—SCN10A—Axon guidance—EGFR—bone cancer	0.000106	0.00126	CbGpPWpGaD
Mexiletine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000106	0.00126	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—NDUFA12—bone cancer	0.000106	0.00126	CbGpPWpGaD
Mexiletine—SCN9A—Developmental Biology—MMP9—bone cancer	0.000106	0.00125	CbGpPWpGaD
Mexiletine—SCN5A—Developmental Biology—CDK4—bone cancer	0.000105	0.00125	CbGpPWpGaD
Mexiletine—SCN5A—Developmental Biology—MET—bone cancer	0.000105	0.00125	CbGpPWpGaD
Mexiletine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000105	0.00124	CbGpPWpGaD
Mexiletine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000104	0.00123	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—NDUFA12—bone cancer	0.000103	0.00123	CbGpPWpGaD
Mexiletine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000103	0.00123	CbGpPWpGaD
Mexiletine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000102	0.00122	CbGpPWpGaD
Mexiletine—SCN2A—Developmental Biology—MMP9—bone cancer	9.7e-05	0.00115	CbGpPWpGaD
Mexiletine—SCN4A—Developmental Biology—MMP9—bone cancer	9.7e-05	0.00115	CbGpPWpGaD
Mexiletine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.36e-05	0.00111	CbGpPWpGaD
Mexiletine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.36e-05	0.00111	CbGpPWpGaD
Mexiletine—SCN10A—Developmental Biology—MMP9—bone cancer	9.35e-05	0.00111	CbGpPWpGaD
Mexiletine—SCN5A—Axon guidance—MMP9—bone cancer	9.21e-05	0.00109	CbGpPWpGaD
Mexiletine—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.87e-05	0.00105	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—NT5C3A—bone cancer	8.75e-05	0.00104	CbGpPWpGaD
Mexiletine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.75e-05	0.00104	CbGpPWpGaD
Mexiletine—SCN5A—Developmental Biology—MMP2—bone cancer	8.74e-05	0.00104	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—NT5C3A—bone cancer	8.57e-05	0.00102	CbGpPWpGaD
Mexiletine—SCN9A—Developmental Biology—EGFR—bone cancer	8.53e-05	0.00101	CbGpPWpGaD
Mexiletine—SCN2A—Developmental Biology—EGFR—bone cancer	7.83e-05	0.000931	CbGpPWpGaD
Mexiletine—SCN4A—Developmental Biology—EGFR—bone cancer	7.83e-05	0.000931	CbGpPWpGaD
Mexiletine—SCN10A—Developmental Biology—EGFR—bone cancer	7.55e-05	0.000898	CbGpPWpGaD
Mexiletine—SCN5A—Axon guidance—EGFR—bone cancer	7.44e-05	0.000885	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—NDUFA12—bone cancer	7.34e-05	0.000873	CbGpPWpGaD
Mexiletine—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.85e-05	0.000814	CbGpPWpGaD
Mexiletine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.75e-05	0.000803	CbGpPWpGaD
Mexiletine—SCN5A—Developmental Biology—MMP9—bone cancer	6.57e-05	0.000781	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—NDUFA12—bone cancer	6.22e-05	0.000739	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—NT5C3A—bone cancer	6.08e-05	0.000723	CbGpPWpGaD
Mexiletine—SCN5A—Developmental Biology—EGFR—bone cancer	5.31e-05	0.000631	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—NT5C3A—bone cancer	5.15e-05	0.000612	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—NDUFA12—bone cancer	4.8e-05	0.00057	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.98e-05	0.000473	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—ENO2—bone cancer	3.83e-05	0.000456	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—ENO2—bone cancer	3.75e-05	0.000446	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—DHFR—bone cancer	3.56e-05	0.000423	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—DHFR—bone cancer	3.48e-05	0.000414	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—GNA11—bone cancer	3.32e-05	0.000395	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—GNA11—bone cancer	3.26e-05	0.000387	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—CYP3A4—bone cancer	3.01e-05	0.000358	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—CYP3A4—bone cancer	2.95e-05	0.000351	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—ENO2—bone cancer	2.66e-05	0.000317	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—GSTP1—bone cancer	2.58e-05	0.000306	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—GSTP1—bone cancer	2.52e-05	0.0003	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—DHFR—bone cancer	2.47e-05	0.000294	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—GNA11—bone cancer	2.31e-05	0.000275	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—ENO2—bone cancer	2.26e-05	0.000268	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—CYP3A4—bone cancer	2.09e-05	0.000249	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—DHFR—bone cancer	2.09e-05	0.000249	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—GNA11—bone cancer	1.96e-05	0.000233	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—GSTP1—bone cancer	1.79e-05	0.000213	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.77e-05	0.000211	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.77e-05	0.00021	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—ENO2—bone cancer	1.74e-05	0.000207	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—DHFR—bone cancer	1.62e-05	0.000192	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—GSTP1—bone cancer	1.52e-05	0.00018	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—GNA11—bone cancer	1.51e-05	0.00018	CbGpPWpGaD
Mexiletine—CYP2B6—Metabolism—PTGS2—bone cancer	1.34e-05	0.000159	CbGpPWpGaD
Mexiletine—CYP2E1—Metabolism—PTGS2—bone cancer	1.31e-05	0.000155	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—GSTP1—bone cancer	1.17e-05	0.000139	CbGpPWpGaD
Mexiletine—CYP2D6—Metabolism—PTGS2—bone cancer	9.28e-06	0.00011	CbGpPWpGaD
Mexiletine—CYP1A2—Metabolism—PTGS2—bone cancer	7.86e-06	9.34e-05	CbGpPWpGaD
Mexiletine—CYP3A4—Metabolism—PTGS2—bone cancer	6.07e-06	7.21e-05	CbGpPWpGaD
